News

News 20.04.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass, April 19, 2026 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced the presentation of new preclinical data across three posters...

News 16.04.2026 Schlieren, Switzerland – April 14, 2026 New Offering Integrates DOPPL’s Patient-Derived Intestinal Organoid Technology with InSphero’s Proven Standardized Screening Model InSphero AG, the global leader in 3D cell-based assays and organ-on-chip systems, today announced the commercial launch of the 3D InSight™ Drug-Induced Gastrointestinal Toxicity (DIGIT) platform, a standardized, high-throughput screening solution for early...

News 15.04.2026 Collaboration supports global LRRK2 Investigative Therapeutics Exchange (LITE) to accelerate development of reliable biomarkers for Parkinson’s disease April 14, 2026 – ZURICH, Switzerland. Biognosys Group, a leading provider of proteomics, metabolomics, and lipidomics solutions, today announced a major collaboration with The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to advance the...

News 14.04.2026 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the “Company”), today announced that...

News 14.04.2026 Schlieren, ZH/Bern – Biognosys will present four scientific talks at this year’s Swiss Proteomics Meeting. The event for proteomics and life sciences will take place on April 23 and 24 at the Holiday Inn Bern – Westside. According to a press release, the Schlieren-based biotech company will participate in the meeting...